Under construction – not a live service
Sign in
Taking people in DenmarkPhase 2

Imaging brain tumors with hyperpolarized pyruvate MRI

Tests a special pyruvate MRI scan in adults with glioblastoma brain tumors.

Key facts

Who runs it
Aarhus Universitet
Where
Aarhus N, DenmarkSee the site
Registry title
MRI with hyperpolarized pyruvate in gliblastoma - a phase II study
Status
Recruiting
Phase
Phase 2
People taking part
10 people, planned
Started
1 Apr 2020
Expected to end
31 Dec 2027
Type of study
Interventional
Record updated
28 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed high-grade glioma (grade 3 or 4) who are about to start radiotherapy.

Age
At least 18 years old.
Sex
All sexes can join.
Disease stage
Newly diagnosed high-grade glioma (grade 3 and 4), scheduled for radiotherapy. WHO performance status 0-2.
Earlier treatment
No previous or current radiation or chemotherapy. No other investigational agents.

Main reasons for not taking part

  • Allergy to pyruvate
  • Cannot have an MRI (for example pacemaker, metal in the body, claustrophobia)
  • Cannot have gadolinium contrast (eGFR 30 mL/min/1.73m2 or less, or earlier reactions to it)
  • Expected remaining survival under 3 months
  • Symptomatic heart disease, or history of alcohol abuse or illicit drug use

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Patients with newly diagnosed high-grade glioma (grade 3 and 4)
  • Scheduled for radiotherapy
  • At least 18 years of age
  • WHO performance status 0-2
  • Women who are not postmenopausal or surgically sterile must have a negative serum or urine pregnancy test performed at time of inclusion in the study. Safe and highly effective contraception must be used throughout the study meaning either hormonal anti-conception or an anti-fertility intrauterine device. If the partner is non fertile or the patient has no sexual activities, this is also accepted
  • Danish speaking
  • Able and willing to comply after informed consent

Who cannot take part

  • Not able or willing to receive radiotherapy
  • Subjects who are receiving any other investigational agents
  • Previous or current treatment by radiation or chemotherapy
  • History of alcohol abuse or illicit drug use
  • Allergy to pyruvate
  • Contraindications to MRI o Pacemaker, neurostimulator or cochlea implant o Metal foreign bodies such as fragments and irremovable piercings o Unsafe medical implants (safety of heart valves, hips and the like must be confirmed) o Intracranial clips or coils o Claustrophobia o Largest circumference including arms > 160 cm
  • Symptomatic cardiac disease (i.e. valve disease, coronary artery disease, arrythmias etc.). Hypertension and hyperlipidemia are allowed
  • Contraindications to gadolinium contrast o eGFR ≤ 30 mL/min/1.73m2 o Previous adverse reactions to gadolinium
  • Predicted remaining survival <3 months

Where in Denmark

  • Aarhus UniversitetAarhus N, DenmarkTaking people

About the trial

What the trial wants to find out

We hypothesis that tumor and therapy related changes in the brain tissue are associated with altered metabolic profiles and this is detectable with hyperpolarized [1-13C]pyruvate MRI.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
MRI with hyperpolarized pyruvate in gliblastoma - a phase II study
Plain-language title
Imaging brain tumors with hyperpolarized pyruvate MRIGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
28 November 2025